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Abstract 
Rationale/Objectives: Research has revealed associative learning deficits among users 
of ecstasy; the present study explored the component processes underlying these 
deficits. Methods: 35 ecstasy users and 62 non-ecstasy users completed a computer-
based, verbal paired-associates learning task. Participants attempted to learn eight 
sequentially presented word pairs. After all eight had been presented, the first member 
of each pair was displayed and participants attempted to recall the second. Eight trials 
were administered. Correct responses on each trial, forgetting at various levels of 
learning, perseveration errors and the rate at which the associations were learned 
(trials to completion) were all recorded. Results: MANOVA revealed that ecstasy 
users performed worse overall and subsequent ANOVAs showed that users performed 
significantly worse on virtually all measures. Regression analysis revealed that over 
half of the ecstasy-group related variance in trials to completion was attributable to 
group differences in initial learning and forgetting. In relation to forgetting, it appears 
that cannabis use may be an important determinant. In relation to rate of learning 
(trials to completion) and initial learning, both ecstasy and cannabis may be 
implicated. Conclusions: There appears to be abundant evidence of associative 
learning deficits among ecstasy users. However, it appears that a range of illicit drugs 
including cannabis and ecstasy may contribute to these deficits.  
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Introduction. 
Developing an understanding of relationships between concepts is a 
fundamental aspect of human learning. One key aspect of this is associative learning, 
which involves forming appropriate links between previously unrelated phenomena. 
The working memory system in general, and the executive in particular are essential 
components in learning new skills before they become automatic, so that learning and 
the acquisition of knowledge is dependent on working memory (Tanji & Hoshi, 
2001). The term associative learning describes the process by which an organism 
develops or reinforces connections between stimulus representations (Rose et al, 
2001). Ecstasy users have been shown to exhibit deficits in aspects of working 
memory functioning (e.g., Fisk et al, 2004; Wareing, et al, 2004) and in view of the 
role of working memory and executive processes in supporting associative learning it 
is possible that users might also experience impairments in learning processes.  
Much of the research in this domain has focussed on animal learning and to 
date the results have been equivocal. While some studies have found MDMA-related 
deficits in aspects of learning (Broening et al, 2001; Frederick et al, 1995; Taylor & 
Jentsch, 2001; Williams et al, 2003) others have not (Frederick & Paule 1997; 
Ricaurte et al, 1993; Romano & Harvey 1994; Winsaeur et al, 2002). In a study 
examining learning in rats, Robinson et al (1993) found that the extent of 5HT 
denervation (72.6%) was not sufficient to produce marked deficits (this may be a sign 
of neurocompensatory changes). More generally, it is possible that the apparent lack 
of MDMA-related deficits in some animal studies is because the tasks are too simple, 
and they do not mirror learning in humans.  
Although some studies in humans have investigated associative learning, this 
is an area that is still under investigated as a number of tasks used relate more to 
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immediate and delayed recall, rather than the learning of associations. Gouzoulis-
Mayfrank et al (2003) used the word-pair learning test of the LGT-3 test battery, 
which requires participants to memorise 20 word pairs consisting of a Turkish word 
and it’s German translation. In the retrieval phase, participants had to identify the 
correct Turkish word corresponding to each German word (out of 5 possible answers). 
Heavy ecstasy users performed worse than non-users in the delayed recall of the word 
pairs, but not the immediate recall component. However, the effect was reduced to 
below statistical significance after control for general knowledge scores.  
Croft et al (2001) studied the relative contributions of ecstasy and cannabis to 
spatial and non-spatial Paired Associates Learning (PAL). Participants were required 
to learn associations between six spatial pairs (spatial) and six colour pairs (non-
spatial). The task began with the participant guessing, then learning the prompted 
association through feedback from the experimenter (yes/no). The task finished when 
the participant correctly reported 18 consecutive associations, and the number of 
guesses required to get to this point was the score (maximum allowed was 180). No 
significant differences were observed between the ecstasy/cannabis group and the 
cannabis only group. A combined drug-user group performed significantly worse than 
controls on the non-spatial PAL. ANCOVA revealed that this effect was more due to 
cannabis than ecstasy. However, the average cannabis abstinence period was only 17 
hours so it was possible that participants were still intoxicated. Also, Croft et al’s 
participants only had a modest lifetime dose of ecstasy.   
Fox et al (2002) also used a spatial PAL task in which participants were 
required to learn the spatial locations of abstract patterns. In the test trials participants 
were first required to learn six pattern-location pairs and then in the next trial eight 
pairings. No significant group differences were observed in the number of errors, the 
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number of presentations required per trial, or the memory score (total number of 
patterns successfully located on initial presentation). The group by trial interaction 
approached significance, and post hoc tests revealed that the ecstasy group made a 
greater number of errors on the 8 pair trials. Rodgers (2000) found that ecstasy users 
were unimpaired during the initial learning phase of the verbal and visual paired 
associates sub-tasks of the Wechsler Memory Scale. However, subsequent deficits in 
the delayed recall of the verbal and visual paired associates were apparent among 
ecstasy users but not among cannabis-only users. 
In addition to deficits in associative learning, basic verbal learning deficits 
have also been observed using the Rey Auditory Verbal Learning Test (RAVLT). 
During trials 1-5, a list of 15 words is read to participants, and they are then required 
to recall as many words as possible in any order; in trial 6 this is repeated with a new 
list of words (interference). Trial 7 requires participants to again recall the original 
list. Finally, participants are given a list of words containing those from the first list 
with phonemic and semantic distractors, and required to circle words that appeared in 
the first list. McCardle et al (2004) found that ecstasy users performed significantly 
worse than non-users on delayed recall (trial 7), and Reneman et al (2000) found that 
ecstasy users recalled significantly fewer words than non-users. Ecstasy-related 
deficits were also observed on trial 1, the total number of words recalled and trials 6 
and 8 in ex-ecstasy users compared to drug-naïve controls (Thomasius et al, 2003).  
A problem with research in this area is that the ecstasy-related deficits 
observed may be at least in part, attributable to cannabis or the concomitant use of 
other drugs. Croft et al (2001) used a battery of neuropsychological tests to compare a 
group of cannabis only users, a combined ecstasy and cannabis group, and a control 
group. No significant differences were observed between the ecstasy/cannabis and the 
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cannabis only groups. However, a combined drug-using group (merging the cannabis 
only and ecstasy/cannabis group) performed worse than controls on working memory 
(forward and backward digit span), information processing, and learning and 
recognition memory. The authors concluded that cannabis, not ecstasy, was 
responsible for the deficits. However, the lifetime ecstasy dose of Croft et al’s 
participants was only 41.9 tablets, which is relatively modest compared to other 
studies (e.g. Morgan et al’s 2002 study in which users consumed over 500 tablets). 
While Croft et al’s results appear to implicate cannabis use, Gouzoulis-Mayfrank et al 
(2000) found an ecstasy/cannabis group (with an average lifetime dose of 93.4 tablets) 
to be impaired relative to a cannabis-only and a non-user group in selective attention, 
a verbal learning task, immediate visual recall, logical thinking and general 
knowledge. However, more recently Dafters et al (2004) found that combined ecstasy-
cannabis users, although worse than drug free controls on various measures of 
episodic memory (free recall and story recall), did not differ significantly from 
cannabis only users on any of the measures that were administered. Furthermore, 
unlike Croft et al’s study, Dafters et al included both a heavy and light ecstasy user 
group, both of which performed similarly and did not differ from the cannabis-only 
users. This being the case, Dafters et al (2004) maintain that that the memory 
impairments obtained were due to cannabis rather than ecstasy. In relation to the 
present study, it is important therefore to consider the extent to which cannabis and 
other drugs might contribute to any apparent ecstasy-group related deficit in 
associative learning. 
Thus the aim of the present study is to determine if users of ecstasy exhibit 
deficits in associative learning while attempting to control for the potentially 
confounding effects of other elicit drugs. In addition to the measures used by other 
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researchers (mainly immediate and delayed recall of words) the test used in the 
present study assesses various measures of forgetting, perseverative errors, and the 
speed with which all associations are learned (trials to completion) which have not yet 
been systematically investigated in ecstasy research. The number of pairs repeated 
correctly on trial one gives a measure of initial learning, and the number of trials 
required for a participant to learn all associations (“trials to completion”) gives an 
overall indication of speed of learning. Forgetting at each level will also be recorded, 
whereby forgetting a response that had previously been recalled correctly once would 
indicate forgetting at level one, forgetting a response that had previously been recalled 
two times would be forgetting at level two, and so on. In addition, the number of 
perseverative errors will be recorded (i.e. giving the same incorrect response on two 
or more consecutive trials). It is expected that ecstasy users will perform worse than 
controls in paired associate learning, more specifically, they will correctly recall fewer 
pairs on trial 1, forget more items, make more perseverative errors, and take more 
trials to learn all associations. An overall deficit in associative learning may provide 
further support for impaired executive function since optimal learning requires the 
effective use of strategies and self-monitoring meta processes. Furthermore, an 
increased number of perseverative responses might be associated with a failure to 
inhibit previously incorrect responses or with an inability to shift mental set. Recalling 
fewer pairs on trial one may in part reflect hippocampal/medial temporal lobe 
impairment, while forgetting well-learned material would suggest a retrieval deficit.  
Method 
Design and Analysis.  
Dependent variables were various measures of associative learning including 
trials to completion, initial learning (number of correct responses in trial 1), 
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perseverative responses, and forgetting at various levels of learning. The independent 
variable was ecstasy user group (users versus non-users). MANOVA was used 
supplemented by separate univariate analyses for each dependent variable. 
Subsequently, for each of the dependent variables, various measures of amphetamine, 
cannabis and cocaine use including lifetime use, frequency of use, average weekly 
dose, amount consumed in the previous 30 days and a categorical user-nonuser 
variable were included as covariates. Following this, in order to establish whether 
heavy ecstasy users were impaired relative to light users a second MANOVA was 
conducted with estimated level of lifetime ecstasy use between participants (heavy 
user- more than 200 tablets, light user - fewer than 200 tablets, and non ecstasy user) 
and the same dependent variables as indicated above.  
In addition to these analyses, the relationship between aspects of illicit drug 
use and associative learning performance was assessed through bivariate correlation. 
This was done separately for measures of ecstasy, cannabis, cocaine and amphetamine 
use. For each of these, it was expected that measures of use would be inversely 
correlated with the measures of learning performance. For each illicit drug five 
separate measures of use were correlated with the five measures of learning 
performance yielding a total of 25 correlations. Given that the drug use measures were 
inter-correlated as were the learning measures, full Bonferroni correction is 
inappropriate (Uitenbroek, 2004). An adjusted Bonferroni significance level of .01 
was computed based on application of the procedure set out by Uitenbroek (2004).  
In order to establish which of the learning processes shared variance with the 
ecstasy-user group variable, hierarchical regression analysis was used. In all cases, 
trials to completion was the dependent variable. The ecstasy user group related 
variance was estimated first by entering this measure as the sole independent variable. 
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Next, measures of initial learning, perseverative responses and forgetting at various 
levels were entered as independent variables in separate regressions. In each case the 
measure of learning performance was entered first followed by ecstasy user group to 
establish how much of the ecstasy user-group related variance was accounted for by 
each learning sub-process.  
 
Participants   
Participants were initially recruited through direct contact with under-
graduates from Liverpool John Moores University, and through the snowball 
technique (Solowij et al, 1992). 62 non-ecstasy users (44 female, mean age 21.3) and 
35 ecstasy users (15 female, mean age 21.66) were recruited. Participants reported 
that they had abstained from ecstasy use for at least 7 days (mean = 12.16 weeks), and 
other psychoactive drugs for at least 24 hours prior to testing. Participants were paid 
15 UK pounds in store vouchers for their participation.   
 
Materials.  
Patterns of drug use and other relevant lifestyle variables were investigated by 
means of a background questionnaire. The questionnaire gauged the use of ecstasy 
and other drugs, as well as age, years of education, general health, and other relevant 
lifestyle variables. In relation to other drugs, participants were asked a range of 
questions including frequency and duration of use and the last time that they had used 
each drug. Participants were also questioned concerning their history of drug use, and 
using a technique developed by Montgomery et al (in press) these data were used to 
estimate total lifetime use for each drug. Average weekly dose and the amount of each 
drug consumed within the previous 30 days were also assessed. Fluid intelligence was 
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measured via Raven’s Progressive Matrices (Raven et al 1998), and pre-morbid 
intelligence was assessed via the National Adult Reading Test (NART, Nelson, 1982).  
Associative Learning. This was assessed via a verbal paired associates task. 
Participants were presented sequentially with the same eight word pairs (taken from 
Fisk, 2003) on a computer screen. For example,  
  DOOR   CASE 
  YEAR   PAGE 
After each presentation, the participant was prompted with the first member of 
each pair and required to recall the second member. Eight such trials were 
administered. The order of presentation was randomised and changed for each trial. 
Measures included the number of correct responses in trial 1 (a measure of initial 
learning), forgetting at various levels, the number of trials required to learn all 
associations, and the number of perseverative errors (giving the same incorrect answer 
consecutively).  
Sleep quality. A screening questionnaire and the Epworth Sleepiness Scale 
(ESS- Johns, 1991) were used to investigate any group differences in sleep quality. 
The ESS is a measure of subjective daytime sleepiness and contains eight items, 
which a participant has to score on a scale of 0 (would never doze off in this situation) 
to 3 (high chance of dozing off in this situation). A total score of all eight items was 
used in the analysis. The screening questionnaire contained a number of questions on 
sleep quality, e.g., hours per night, “how refreshed do you feel in the morning”, in 
addition to relevant lifestyle questions relating to cigarette and alcohol consumption.   
 
Procedure.  
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The tests were administered under controlled laboratory conditions. A 
computer running on MS-DOS was used for the associative learning task. Tasks were 
administered in the following order: Health/education questionnaire, ecstasy and drug 
use background questionnaire, sleep questionnaires, associative learning, NART and 
finally Raven’s progressive matrices. Overall, testing took two to three hours per 
person. The study was approved by the Ethics Committee of Liverpool John Moores 
University, and was administered in accordance with the ethical guidelines of the 
British Psychological Society.  
Results 
 Average age, years of education, fluid intelligence, premorbid intelligence and 
other background variables for the two groups are set out in Table 1. Statistical tests 
(ANOVA, t-test) revealed that there were no significant differences between the 
groups regarding these variables, so they are not discussed further.  
   <Insert table 1 about here> 
 Inspection of Table 2 reveals that the use of other drugs was commonplace 
among the ecstasy group, but was restricted mainly to the use of cannabis among the 
control group. The Ecstasy users had a lifetime dose of cannabis nearly twice that of 
the controls (2128 joints compared to 1082 joints), in addition to using it more 
frequently (2.45 times per week, compared to 0.77 times), and having smoked more in 
the last 30 days (17.52 joints compared to 7.91 joints). There were significant group 
differences in the amount smoked in the last 30 days t(37.74) = 2.07, and the 
frequency of use t(32.56) = 3.20, p<.05 in both cases. However the difference in 
lifetime use was not statistically significant: t(41.31)=1.80, p>.05. (As Levene’s test 
was significant, degrees of freedom have been adjusted accordingly.) The ecstasy 
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group reported an average total lifetime dose of ecstasy of 315 tablets; of 
amphetamine, 4 grams (n=8); and of cocaine, 18.96 grams (n=15). The average 
frequency of use for ecstasy was 0.4 times per week, and for cocaine, 0.26 times per 
week (n=15).  
   <Insert table 2 about here>  
 
Ecstasy users performed worse on all measures of associative learning. Users 
required more trials to learn the pairings; they scored lower on the measure of initial 
learning (the number of correct responses on Trial 1); and they made more 
perseverative responses. However, Table 3 reveals that the group differences were 
less pronounced for the measures of forgetting. Indeed, the means reported in the 
Table indicate that once the material had been learned to a moderate degree, 
forgetting was a rare event among both users and nonusers. Thus, for example, once a 
response had been successfully learned for four or more consecutive trials, there was 
no occurrence of forgetting in the nonuser group and only seven of the 35 users forgot 
a previously learned response. MANOVA revealed that the ecstasy-related group 
difference on the measures of associative learning was statistically significant, F(7,89) 
= 4.64, p<.001. Furthermore, subsequent univariate analyses revealed significant 
group differences on each of the measures with the exception of forgetting at levels 2 
and 4 (see Table 3). 
  <Insert Table 3 about here> 
It is possible that some or all of these effects might have been attributable to 
the effects of other drugs. To address this possibility, the preceding analysis was 
repeated five times with different measures of amphetamine, cannabis, and cocaine 
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use as covariates. In the first analysis, measures of lifetime use of each of these other 
drugs were included; in the second, the number of times each drug was consumed 
each week; in the third, the amount of each drug consumed within the last 30 days; in 
the fourth, the average weekly dose (i.e., total amount consumed divided by the length 
of use in weeks); and in the fifth, categorical variables in which users and non users of 
each individual drug were coded as 0 or 1 respectively. Thus each of the analyses 
contained specific measures of amphetamine, cannabis, and cocaine use as covariates. 
This was done for the multivariate data yielding 5 multivariate outcomes and for each 
of the seven measures of associative learning yielding 35 univariate analyses in total. 
The results are set out in Table 4. In the analyses, the multivariate effect of ecstasy 
user group and the univariate ecstasy user group effects on trials to completion and 
perseverative errors remained statistically significant. The same was true in relation to 
forgetting at level three although this result needs to be treated with caution as all non-
ecstasy users scored zero on this measure. Somewhat less reliable were the group 
differences in initial learning where measures of the frequency of other drug use and 
the categorical other drug use/non use covariates reduced the ecstasy-related group 
differences to below statistical significance. Similarly, ecstasy-group related 
differences in forgetting were reduced to below statistical significance following 
control for total lifetime use and average weekly dose of the other drugs.  
<Insert table 4 about here> 
In relation to the cannabis measures that were included in each of the 35 
ANCOVA analyses referred to in the previous paragraph, homogeneity of regression 
was obtained in 31 out of 35 cases, p> .05 for the covariate by ecstasy user group 
interaction. The exceptions were: (i) in relation to the cannabis user group covariate, 
for the initial learning measure; (ii) again in relation to the cannabis user group 
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covariate, for the forgetting at level 4 measure; (iii) regarding the average weekly 
dose of cannabis covariate, for the forgetting at level 3 measure; and (iv) in relation to 
the frequency of cannabis use covariate, for the forgetting at level 1 measure. For 
these exceptional cases, the covariate by ecstasy user group interactions were all 
statistically significant; p<.05 in all cases. 
Since the number of cocaine and amphetamine users among the non-ecstasy 
user group was small, it was not possible to properly test for homogeneity of 
regression in relation to the cocaine and amphetamine measures. Given these 
limitations, we cannot entirely rule out the possibility that other drugs may have 
played a part in accounting for the results obtained here. Indeed the correlations set 
out in Table 5 reveal that various aspects of other drug use were correlated with 
associative learning processes. Assuming a value of α = .01, forgetting, both for well 
learned and for less well-learned material, was significantly correlated with total 
lifetime dose and average weekly dose of cannabis. Perseverative responses were 
significantly correlated with the frequency of amphetamine use. Initial learning was 
significantly correlated with lifetime cannabis use, the frequency of cannabis and 
cocaine use, cannabis use during the previous 30 days, and the average weekly dose 
of ecstasy. Consistent with the results of the MANOVA, the ecstasy user group 
variable was significantly correlated with all measures of learning performance.  
<Insert table 5 about here> 
In relation to possible ecstasy dosage effects, Table 6 reveals that for the most 
part while both ecstasy user groups performed worse than non-users, there is little 
difference between the high lifetime ecstasy dose and the low lifetime ecstasy dose 
user groups. MANOVA with level of ecstasy use as the independent variable (high 
lifetime dose n=18, low lifetime dose n=17, non user n=62) and the seven measures of 
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learning performance as dependent variables yielded a significant multivariate effect 
of level of ecstasy use F(14,178) = 5.19, p<.001. Table 6 reveals that significant 
differences were also obtained for each of the component learning measures. Pairwise 
comparisons revealed that non users performed significantly better than both user 
groups in trials to completion, p<.05 via Tukey’s test. Equally non users were 
significantly better than heavy users on the initial learning measure, p<.05. Non users 
were also significantly better than light users on all of the forgetting measures, p<.05. 
The only significant differences between the two ecstasy user groups were for 
forgetting at levels 2, 3, and 4 where paradoxically light users performed significantly 
worse then heavy users, p<.05, via Tukey’s test.  
<Insert Table 6 about here>  
 Regarding the ecstasy-group related variance in trials to completion, it is 
important to emphasise that the ecstasy-group related variance potentially arises from 
a range of sources. In addition to using ecstasy, a range of other drugs was also used 
and there may also be premorbid differences between the two groups, as well as 
differences in psychological affect. Thus the ecstasy-group related variance might 
have arisen from any one of these sources. The focus here is to establish which sub-
processes were responsible for the difference in overall learning performance among 
this group of poly-substance abusers. 
Table 7 reveals that the ecstasy-group related variance amounted to 21.8% of 
the total variance in associative learning (as indicated by the R squared increment of 
.218). In subsequent analyses, ecstasy use was entered in the regression equation 
following the inclusion of each specific learning sub-process. This makes it possible 
to establish how much of the ecstasy-group related variance was accounted for by 
each of the learning sub-processes. Inspection of Table 7 reveals that following 
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statistical control for group differences in initial learning (as measured by the number 
of correct responses in Trial 1), the residual ecstasy-group related variance amounts to 
8.6%. Thus over half of the ecstasy-group related variance is accounted for by 
individual differences in the level of initial learning. Three other regression models 
were evaluated. Prior control for group differences in perseverative responses reduced 
the ecstasy-related variance from 21.8% to 13.4%. Inclusion of forgetting at level one 
and at higher levels in the first stage of the hierarchy removed at least half of the 
ecstasy-group related variance in both cases.  
   <Insert Table 7 about here> 
Discussion. 
 As expected, the results demonstrated an ecstasy-group related deficit in 
associative learning. The ecstasy user group performed worse on all measures of 
associative learning, they required more trials to learn the associations, achieved 
fewer correct responses on trial one, produced more perseverative responses, and 
demonstrated a greater propensity to forget previously learned responses, especially 
those that were not well learned. Furthermore, when indices of cannabis, cocaine, and 
amphetamine use (lifetime dose, frequency of use, average weekly dose, amount 
consumed in the last 30 days, and a categorical variable of user/non-user) were 
included as covariates, the ecstasy-group related deficits in trials to completion and 
perseverations remained significant. However, differences in initial learning fell to 
below statistical significance with control for other drug use (frequency of use, 
user/non-user). In addition, group differences in forgetting were reduced to below 
statistical significance following control for lifetime, and average weekly dose of 
other drugs.  
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As some of the apparent ecstasy-group related effects were reduced to below 
statistical significance following controls for the use of other drugs and since 
homogeneity of regression was not obtained in all cases or could not be tested, the 
possibility that other drugs might affect associative learning performance cannot be 
excluded. Indeed the correlations obtained in the present study suggest that cannabis 
use may affect a number of aspects of learning performance. However, the 
correlations set out in Table 5 do need to be treated with caution. Most of them were 
modest in scale so that the variables in question shared only a relatively small amount 
of variance with the learning measures. Furthermore, the Bonferroni correction that 
was used is based on the assumption that it is appropriate to consider expectations for 
each illicit drug separately; hence the procedure is based on a total of 25 comparisons 
where both the outcome variables and the predictor variables were intercorrelated. If a 
more conservative Bonferroni correction procedure was employed, then with 100 
independent correlations, a value for α = .0005 would be appropriate. At this level 
only two of the correlations would be statistically significant, specifically, 
perseverative responses with the frequency of amphetamine use and the ecstasy user-
nonuser variable with trials to completion. 
 It was noteworthy that the apparent ecstasy-group effect does not appear to be 
directly related to the level of lifetime ecstasy use, since MANOVA revealed that, 
relative to nonusers, heavy ecstasy users were no more impaired than light ecstasy 
users. This outcome is not readily explained. It may be that no straightforward 
relationship exists between the total number of tablets taken and the risk of a 
neurotoxic dose (O’Shea et al 1998). Rather the likelihood of MDMA related 
impairment is associated with the co-occurrence of a number of factors, which are not 
necessarily related to the total number of tablets consumed such as the number of 
 18 
tablets ingested on a single occasion and the conditions (ambient temperature, level of 
hydration, background sound level) prevailing at the time (O’Shea et al 1998). Thus 
an individual who typically consumes a modest dose, relatively infrequently but over 
a long period of time may have a high lifetime dose but not demonstrate any 
substantial learning deficits. 
Turning to the results of the regression analysis, it was revealed that ecstasy 
user group accounted for approximately 22% of the total variance in trials to 
completion. All of the component measures of learning performance substantially 
reduced the ecstasy-group related variance. The greatest degree of attenuation was 
achieved by the level of initial learning (number correct in trial 1). The various 
measures of forgetting each reduced the ecstasy group related variance by about one 
half while for perseverative responses the degree of attenuation was around 40%. 
Thus the ecstasy-group related effect appears to be mediated through all of the 
learning sub processes. Taken together with the results of the MANOVA, the 
robustness of the group difference in trials to completion following the various 
ANCOVA analyses is consistent with an ecstasy-mediated effect in relation to this 
aspect of learning. However, it is at least possible that some of the attenuation 
produced by the level of initial learning and by forgetting may have been due to other 
drugs such as cannabis. Such a possibility would be consistent with Dafters et al 
(2004) and Croft et al’s (2001) results linking cognitive deficits to cannabis use rather 
than ecstasy. However, in relation to the other learning measures, statistical controls 
for group differences in various measures of cannabis consumption did not eliminate 
the overall ecstasy related group difference.  
There are a number of limitations of the present study that need to be 
acknowledged. In a quasi-experimental design such as that adopted in the present 
 19 
study, it is possible that the groups may have differed on some variable other than 
ecstasy. Some possibilities can be excluded such as intelligence (NART and Raven’s) 
and aspects of sleep quality. However others such as general health, nutrition, or some 
premorbid condition cannot be ruled out. Furthermore, we relied on self-reports of 
drug use and so it is possible that there were inaccuracies in this data. There is also no 
guarantee of the purity of drugs used, and the quantitative amounts per tablet, gram 
etc (Cole et al 2002). Furthermore, due to limited resources, we were unable to 
provide an objective measure of recent drug use (e.g. from hair and urine samples). 
However, most published studies testing cognitive deficits among ecstasy users have 
not used these techniques (e.g. Fox et al, 2002; Morgan, 1998; Morgan, 1999; Parrot 
and Lasky, 1998, Rodgers, 2000, Wareing et al, 2000). All participants reported being 
drug free for 24 hours, and ecstasy free for at least 7 days (average abstinence period 
was actually 12 weeks), and we have no reason to believe this information to be false 
(participants were not informed that they would be excluded prior to testing).  
In conclusion, the present study further supports evidence for cognitive 
deficits in ecstasy users. Individual differences in initial learning, perseverative 
responses and forgetting all appear to be important determinants of verbal associative 
learning deficits in these individuals. However, while some of these impairments 
appear to be related to ecstasy use, others may be attributable to other drugs such as 
cannabis. 
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Table 1 
Age, Years of Education, Intelligence, and Sleep Quality for Ecstasy Users and Non 
Ecstasy Users 
 Ecstasy Users Non Ecstasy 
Users 
 Mean S.D. Mean S.D. 
Age (Years) 
 
21.66 1.64 21.30 1.79 
Years of Education 
 
15.77 1.88 15.36 2.12 
Ravens Progressive 
Matrices (maximum 
60) 
49.94 4.55 48.13 5.27 
NART (maximum 50) 
 
28.91 5.98 29.76 5.80 
Hours Sleep per Night 
 
  8.11 1.56   8.01 1.27 
Epworth Sleep Scale 
(Maximum 24) 
  6.38 3.38   5.97 3.03 
Self Report Health * 
 
  3.74 0.74   3.84 0.81 
 
* The self report health measure scores range from 1 (very poor) to 5 (very good) 
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Table 2.  
Indicators of Drug Use Among Ecstasy Users and Non Ecstasy Users 
 
 Ecstasy Users Non Ecstasy Users 
 
 Mean S.D. n Mean S.D. n 
Total Use       
     Ecstasy (tablets)   315.30    330.10 35        
     Amphetamine (grams)       4.00        3.86   8       4.00       -   1 
     Cannabis (joints) 2128.71  2401.96 26 1082.54 1439.33 18 
     Cocaine(grams) 
 
    18.96      22.03 15       -       -    
Frequency of Use (times 
per week) 
      
     Ecstasy       0.40        0.34 35    
     Amphetamine       0.04        0.04   5       -            -  
     Cannabis       2.45        2.40 25       0.77        0.90 18 
     Cocaine 
 
      0.26        0.23 15       -       -  
Amount Used During 
Previous 30 Days 
      
     Ecstasy (tablets)       3.38        3.58 34    
     Amphetamine (grams)       1.20        2.68   5        -       -  
     Cannabis (joints)     17.52      18.26 24       7.91      11.03 16 
     Cocaine(grams) 
 
      1.23        1.77 13        -        -  
Average Weekly Dose       
     Ecstasy (tablets)       1.67        1.31 35    
     Amphetamine (grams)       0.10        0.20   8       0.01       -   1 
     Cannabis (joints)       7.75        8.73 25       5.11        9.94 18 
     Cocaine(grams) 
 
      0.14        0.24 15        -         -  
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Table 3 
 
Performance on Associative Learning Measures for Ecstasy Users and Non-Ecstasy 
Users. 
 
 Ecstasy Users    
 
Non Ecstasy 
Users 
F (1,95)  
 
 Mean S.D. Mean S.D.  
 
Trials to Completion 
 
6.11 1.94 4.32 1.46 26.54*** 
Number of Correct 
Responses in Trial 1 
 
2.97 2.01 4.32 2.01 10.14** 
Number of 
Perseverative 
responses 
0.69 1.16 0.16 0.66   8.13** 
 
Number Forgotten 
at: 
 
     
Level 1 0.86 1.03 0.39 0.75   6.61* 
 
Level 2 0.26 0.66 0.10 0.35   2.47 
 
Level 3 0.14 0.36 0.00 0.00 10.12** 
 
Level 4 
 
0.06 0.24 0.00 0.00   3.68 
 
 
*** p<.001; ** p<.01; * p<.05 
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Table 4 
Ecstasy User Group Effect (F values) on Measures of Associative Learning Following 
Statistical Controls for Various Measures of Amphetamine, Cannabis, and Cocaine 
Use
1
. 
 
 Covariate Measures: 
 
 Total 
Use 
Times 
used per 
week 
Amount 
Consumed 
in the 
previous 
30 days 
Average 
Weekly 
Dose  
Ever 
Used
2
 
 
Multivariate Effect  
(d.f. = 7,85) 
 
3.16* 4.16*** 5.20*** 4.10*** 3.64** 
Trials to Completion 
 
18.71*** 18.06*** 21.78*** 23.76*** 15.45*** 
Number of Correct 
Responses in Trial 1 
 
6.21* 2.65 4.27* 7.70* 0.73 
Number of Perseverative 
responses 
 
4.17* 7.54** 12.26*** 8.13** 4.52* 
Forgetting: Number 
Forgotten at level 1 
 
2.30 5.80* 6.95** 3.75 7.23** 
Forgetting: Number 
Forgotten at level 2 
 
2.26 5.98* 4.94* 2.74 6.05* 
Forgetting: Number 
Forgotten at level 3 
 
5.53* 16.76*** 18.83*** 7.28** 7.72** 
Forgetting: Number 
Forgotten at level 4 
 
3.39 0.73 0.53 3.82 6.84* 
 
1. Separate measures relating to the use of each of the three drugs were entered 
as covariates in each analysis. For all univariate analyses, degrees of freedom 
were 1,91. Unless otherwise noted, the units were as follows: cannabis - 
number of joints; amphetamine and cocaine – grams. Nonusers of the drug in 
question were coded as zero on the particular measure concerned. 
2. Categorical variable coded 0 = user, 1 = nonuser 
 
*** p<.001; ** p<.01; * p<.05 
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Table 5 
Correlations Between Various Measures of Learning Performance and Measures of 
Illicit Drug Use. 
 
 Trials to 
Completion 
Initial 
Learning 
Perseverative 
Responses 
Forgetting 
Level 1 
Forgeting 
Levels 2-7 
Total Use      
    Ecstasy   .193 -.226   .162 .146 -.045 
    Cannabis   .281* -.242* -.039 .309* .360* 
    Cocaine   .092 -.155   .274 .047 -.012 
    Amphetamine   .085   .058   .172 .093 .074 
      
Frequency      
    Ecstasy   .218 -.173   .004 .189 .066 
    Cannabis   .165 -.320* -.102 -.016 .057 
    Cocaine   .169 -.248*   .139 .148 -.014 
    Amphetamine   .143   .107   .331* .085 -.058 
      
Use in Last 30 
Days 
     
    Ecstasy   .226 -.127   .075 .154 .082 
    Cannabis   .198 -.279* -.052 -.037 .000 
    Cocaine   .092 -.154   .036 .109 -.038 
    Amphetamine -.054   .106 -.040 .051 -.035 
      
Average Weekly 
Dose 
     
    Ecstasy   .234 -.260*   .149 .100 -.038 
    Cannabis   .235 -.230 -.032 .266* .305* 
    Cocaine   .042 -.107   .113 .005 .014 
    Amphetamine -.033   .103 -.002 .057 -.025 
      
User/Non User      
    Ecstasy -.466**   .310* -.281* -.259* -.281* 
    Cannabis -.221   .245* .013 -.075 -.100 
    Cocaine -.302*   .345* -.202 -.075 -.078 
    Amphetamine -.167   .184 -.072 -.078 -.143 
 
N=97 
 
** p<.001; * p< .01; one tailed.  
A Bonferroni corrected significance level of α  = .01 was used 
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Table 6  
Performance on Associative Learning Measures for Ecstasy Users with High and Low 
Lifetime Dose and Non-Ecstasy Users. 
 
 High lifetime 
ecstasy dose 
>200 tablets
1
 
 
Low lifetime 
ecstasy dose 
≤ 200 tablets2 
Non ecstasy 
user 
F (1,95)  
 
 Mean 
 
S.D. Mean S.D. Mean S.D.  
 
Trials to 
Completion 
 
 
5.67 
 
1.28 
 
6.59 
 
2.40 
 
4.32 
 
1.46 
 
14.92*** 
Number of 
Correct 
Responses in 
Trial 1 
 
2.67 1.81 3.29 2.20 4.32 2.01   5.49** 
Number of 
Perseverative 
responses 
0.67 1.28 0.71 1.05 0.16 0.66   4.03* 
 
Number 
Forgotten at: 
 
       
Level 1 0.72 
 
0.83 1.00 1.22 0.39 0.75   3.75* 
Level 2 0.06 
 
0.24 0.47 0.87 0.10 0.35   4.75* 
Level 3 0.00 
 
0.00 0.29 0.47 0.00 0.00 16.15*** 
Level 4 
 
0.00 
 
0.00 0.12 0.33 0.00 0.00   5.17** 
 
*** p<.001; ** p<.01; * p<.05 
 
1. n=18; mean lifetime number of tablets consumed = 520, range = 219 to1682 
2. n=17; mean lifetime number of tablets consumed = 98, range = 15 to192 
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Table 7. 
Variance in Associative Learning Uniquely Associated with Ecstasy User Group 
Following Statistical Controls for the Effects of Other Independent Variables 
 
 
 
Regression 
Model 
 
Independent Variables in the Model 
Prior to the Inclusion of Ecstasy User 
Group 
 
 
Total R 
squared 
 
R squared 
increment 
associated with 
Ecstasy User 
Group 
 
0 None 
 
.218 .218*** 
1 Number of Correct Responses in Trial 1 
 
.454 .086*** 
2 Number of Perseverative responses .304 .134*** 
 
3 Number Forgotten at level 1 
 
.445 .109*** 
4 Number Forgotten at levels 2, 3 and 4 
 
.405 .091*** 
 
*** p<.001; ** p<.01; * p<.05 
 
  
 
 
